Purification and Characterization of an Inhibitor (Soluble Tumor Necrosis Factor Receptor) for Tumor Necrosis Factor and Lymphotoxin Obtained from the Serum Ultrafiltrates of Human Cancer Patients

Serum ultrafiltrates (SUF) from human patients with different types of cancer contain a blocking factor (BF) that inhibits the cytolytic activity of human tumor necrosis factor α (TNF-α) in vitro. BF is a protein with a molecular mass of 28 kDa on reducing sodium dodecyl sulfate/polyacrylamide gel e...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 87; no. 22; pp. 8781 - 8784
Main Authors Gatanaga, Tetsuya, Hwang, Chenduen, Kohr, William, Cappuccini, Fabio, Lucci, Joseph A., Edward W. B. Jeffes, Lentz, Rigdon, Tomich, John, Yamamoto, Robert S., Granger, Gale A.
Format Journal Article
LanguageEnglish
Published Washington, DC National Academy of Sciences of the United States of America 01.11.1990
National Acad Sciences
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Serum ultrafiltrates (SUF) from human patients with different types of cancer contain a blocking factor (BF) that inhibits the cytolytic activity of human tumor necrosis factor α (TNF-α) in vitro. BF is a protein with a molecular mass of 28 kDa on reducing sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE). The active material was purified to homogeneity by a combination of affinity chromatography, PAGE, and high-pressure liquid chromatography. Amino acid sequence analysis revealed that BF is derived from the membrane TNF receptor. Purified BF blocks the lytic activity of recombinant human and mouse TNF-α and recombinant human lymphotoxin on murine L929 cells in vitro. However, BF inhibits the lytic activity of TNF-α more effectively than it does that of lymphotoxin. The BF also inhibits the necrotizing activity of recombinant human TNF-α when coinjected into established cutaneous Meth A tumors in BALB/c mice. The BF may have an important role in (i) the regulation and control of TNF-α and lymphotoxin activity in cancer patients, (ii) interaction between the tumor and the host antitumor mechanisms, and (iii) use of systemically administered TNF-α in clinical trials with human cancer patients.
AbstractList Serum ultrafiltrates (SUF) from human patients with different types of cancer contain a blocking factor (BF) that inhibits the cytolytic activity of human tumor necrosis factor alpha (TNF-alpha) in vitro. BF is a protein with a molecular mass of 28 kDa on reducing sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE). The active material was purified to homogeneity by a combination of affinity chromatography, PAGE, and high-pressure liquid chromatography. Amino acid sequence analysis revealed that BF is derived from the membrane TNF receptor. Purified BF blocks the lytic activity of recombinant human and mouse TNF-alpha and recombinant human lymphotoxin on murine L929 cells in vitro. However, BF inhibits the lytic activity of TNF-alpha more effectively than it does that of lymphotoxin. The BF also inhibits the necrotizing activity of recombinant human TNF-alpha when coinjected into established cutaneous Meth A tumors in BALB/c mice. The BF may have an important role in (i) the regulation and control of TNF-alpha and lymphotoxin activity in cancer patients, (ii) interaction between the tumor and the host antitumor mechanisms, and (iii) use of systemically administered TNF-alpha in clinical trials with human cancer patients.
Serum ultrafiltrates (SUF) from human patients with different types of cancer contain a blocking factor (BF) that inhibits the cytolytic activity of human tumor necrosis factor α (TNF-α) in vitro. BF is a protein with a molecular mass of 28 kDa on reducing sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE). The active material was purified to homogeneity by a combination of affinity chromatography, PAGE, and high-pressure liquid chromatography. Amino acid sequence analysis revealed that BF is derived from the membrane TNF receptor. Purified BF blocks the lytic activity of recombinant human and mouse TNF-α and recombinant human lymphotoxin on murine L929 cells in vitro. However, BF inhibits the lytic activity of TNF-α more effectively than it does that of lymphotoxin. The BF also inhibits the necrotizing activity of recombinant human TNF-α when coinjected into established cutaneous Meth A tumors in BALB/c mice. The BF may have an important role in (i) the regulation and control of TNF-α and lymphotoxin activity in cancer patients, (ii) interaction between the tumor and the host antitumor mechanisms, and (iii) use of systemically administered TNF-α in clinical trials with human cancer patients.
Serum ultrafiltrates (SUF) from human patients with different types of cancer contain a blocking factor (BF) that inhibits the cytolytic activity of human tumor necrosis factor {alpha} (TNF-{alpha}) in vitro. BF is a protein with a molecular mass of 28kDa on reducing sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE). The active material was purified to homogeneity by a combination of affinity chromatography, PAGE, and high-pressure liquid chromatography. Amino acid sequence analysis revealed that BF is derived from the membrane TNF receptor. Purified BF blocks the lytic activity of recombinant human and mouse TNF-{alpha} and recombinant human lymphotoxin activity of TNF-{alpha} and recombinant human lymphotoxin on murine L929 cells in vitro. However, BF inhibits the lytic activity of TNF-{alpha} more effectively than it does that of lymphotoxin. The BF also inhibits the necrotizing activity of recombinant human TNF-{alpha} when coinjected into established cutaneous Meth A tumors in BALB/c mice. The BF may have an important role in (i) the regulation and control of TNF-{alpha} and lymphotoxin activity in cancer patients, (ii) interaction between the tumor and the host antitumor mechanisms, and (iii) use of systemically administered TNF-{alpha} in clinical trials with human cancer patients.
Serum ultrafiltrates (SUF) from human patients with different types of cancer contain a blocking factor (BF) that inhibits the cytolytic activity of human tumor necrosis factor alpha (TNF- alpha ) in vitro. BF is a protein with a molecular mass of 28 kDa on reducing sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE). The active material was purified to homogeneity by a combination of affinity chromatography, PAGE, and high-pressure liquid chromatography. The BF may have an important role in (i) the regulation and control of TNG- alpha and lymphotoxin activity in cancer patients, (ii) interaction between the tumor and the host antitumor mechanisms, and (iii) use of systemically administered TNF- alpha in clinical trials with human cancer patients.
Author Hwang, Chenduen
Lucci, Joseph A.
Cappuccini, Fabio
Edward W. B. Jeffes
Gatanaga, Tetsuya
Yamamoto, Robert S.
Lentz, Rigdon
Granger, Gale A.
Tomich, John
Kohr, William
AuthorAffiliation Department of Molecular Biology and Biochemistry, University of California, Irvine 92717
AuthorAffiliation_xml – name: Department of Molecular Biology and Biochemistry, University of California, Irvine 92717
Author_xml – sequence: 1
  givenname: Tetsuya
  surname: Gatanaga
  fullname: Gatanaga, Tetsuya
– sequence: 2
  givenname: Chenduen
  surname: Hwang
  fullname: Hwang, Chenduen
– sequence: 3
  givenname: William
  surname: Kohr
  fullname: Kohr, William
– sequence: 4
  givenname: Fabio
  surname: Cappuccini
  fullname: Cappuccini, Fabio
– sequence: 5
  givenname: Joseph A.
  surname: Lucci
  fullname: Lucci, Joseph A.
– sequence: 6
  fullname: Edward W. B. Jeffes
– sequence: 7
  givenname: Rigdon
  surname: Lentz
  fullname: Lentz, Rigdon
– sequence: 8
  givenname: John
  surname: Tomich
  fullname: Tomich, John
– sequence: 9
  givenname: Robert S.
  surname: Yamamoto
  fullname: Yamamoto, Robert S.
– sequence: 10
  givenname: Gale A.
  surname: Granger
  fullname: Granger, Gale A.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19465384$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/2174164$$D View this record in MEDLINE/PubMed
https://www.osti.gov/biblio/5822267$$D View this record in Osti.gov
BookMark eNqFkk1v1DAQhiNUVNrCmQsgC4mvw25tx04ciQtaUVppRSvani3HGbOuEnuxHdTy-_hhONqlpRKCi5OZeWbeN_HsFzvOOyiKpwTPCa7Lw7VTcS7qOaX5FORBsUdwQ2YVa_BOsYcxrWeCUfao2I_xCmPccIF3i11KakYqtlf8PBuDNVarZL1DynVosVJB6QTB_tgkvcl5dOJWtrXJB_T23Pdj2wO6GIccfgYdfLQRHeWuHH8BDev88g6ZHP2dmXSWN8N65ZO_tg6dtklZBx0ywQ8orQCdQxgHdNmnoIydzgRxcnI8DtnMQjkNAZ1lg-BSfFw8NKqP8GT7PCgujz5eLI5ny9NPJ4sPy5muGE8zVnECHTUtb2tG26pjpWhUZxrNKtWQrm4Nqesauo52DHIaFFGEtMJ0XUUMLg-K95u567EdoNNZO6heroMdVLiRXll5v-LsSn713yXnmJW5_eWm3cdkZdQ2gV5p7xzoJLmglFZ1hl5vNYL_NkJMcrBRQ98rB36MUmBS5ln0vyDhQvCKswwebsDpDmIAc2uYYDktkZyWSIpaUiqnJcodz__8zlt-uzW5_mpbV1Gr3oR8HTbejW3yny7FxL3YcpPA7_I9oTf_BKQZ-z7Bdcrksw15FfMC3TkqOa9KXP4CykL5Pw
CODEN PNASA6
CitedBy_id crossref_primary_10_1128_mcb_11_12_5954_5962_1991
crossref_primary_10_1016_S0021_9258_18_55273_X
crossref_primary_10_1016_j_bbmt_2011_11_031
crossref_primary_10_1007_BF02577546
crossref_primary_10_1002_eji_1830250304
crossref_primary_10_1007_BF01262570
crossref_primary_10_1098_rspb_1991_0096
crossref_primary_10_1007_BF01884569
crossref_primary_10_1007_BF00402229
crossref_primary_10_1007_BF01636787
crossref_primary_10_1177_014860719201600602
crossref_primary_10_1016_S0889_857X_05_70027_2
crossref_primary_10_1093_oxfordjournals_annonc_a058593
crossref_primary_10_1046_j_1365_2796_2000_00685_x
crossref_primary_10_1111_j_1348_0421_1993_tb01708_x
crossref_primary_10_1016_S0165_2427_97_00136_0
crossref_primary_10_1046_j_1365_2567_1998_00481_x
crossref_primary_10_1097_01_shk_0000223127_41641_f4
crossref_primary_10_1097_00005373_199507000_00015
crossref_primary_10_3389_fimmu_2022_837842
crossref_primary_10_1080_10408360091174187
crossref_primary_10_1002_cncr_20314
crossref_primary_10_1016_S0165_2427_00_00244_0
crossref_primary_10_3109_00365519409085472
crossref_primary_10_1111_j_1471_0528_1997_tb10981_x
crossref_primary_10_1152_ajprenal_00153_2007
crossref_primary_10_1007_BF02032887
crossref_primary_10_1111_j_1476_5381_1996_tb15214_x
crossref_primary_10_1016_S0021_9258_18_98395_X
crossref_primary_10_1007_BF00309234
crossref_primary_10_1089_105072504323030906
crossref_primary_10_3109_08039488_2015_1122079
crossref_primary_10_1002_1097_0142_19931015_72_8_2433__AID_CNCR2820720822_3_0_CO_2_L
crossref_primary_10_1016_S0928_8244_03_00113_5
crossref_primary_10_1006_clin_1996_4307
crossref_primary_10_1007_BF02505279
crossref_primary_10_1007_BF02918612
crossref_primary_10_1111_j_1365_2249_1993_tb08184_x
crossref_primary_10_1002_hep_1840160322
crossref_primary_10_1016_S0021_9258_18_55141_3
crossref_primary_10_1016_j_scispo_2022_05_006
crossref_primary_10_1080_15321819508013551
crossref_primary_10_1007_s12026_011_8228_8
crossref_primary_10_1007_BF01489489
crossref_primary_10_1177_096805199500200202
crossref_primary_10_1016_S0301_0082_98_00045_8
crossref_primary_10_1007_BF00364965
crossref_primary_10_1056_NEJM199606273342603
crossref_primary_10_1006_cimm_2000_1622
crossref_primary_10_1089_jir_1995_15_143
crossref_primary_10_1016_0736_5748_94_00071_A
crossref_primary_10_1007_BF00422933
crossref_primary_10_1002_stem_5530110206
crossref_primary_10_1016_S0021_9258_18_53839_4
crossref_primary_10_1182_blood_2008_03_143412
crossref_primary_10_1016_S0928_4680_02_00056_1
crossref_primary_10_1016_j_bbadis_2024_167122
crossref_primary_10_1016_S0950_3579_05_80186_4
crossref_primary_10_1016_0002_9378_92_91788_C
crossref_primary_10_3109_02841869509094034
crossref_primary_10_1016_S0021_9258_17_34057_7
crossref_primary_10_1042_BCJ20190462
crossref_primary_10_1093_toxsci_kfp163
crossref_primary_10_3390_ijms21165731
crossref_primary_10_1002__SICI_1097_0215_19971210_73_6_875__AID_IJC19_3_0_CO_2_3
crossref_primary_10_1016_j_biologicals_2007_05_004
crossref_primary_10_1016_0952_7915_94_90119_8
crossref_primary_10_1016_S0898_6568_98_00018_7
crossref_primary_10_1371_journal_ppat_1003737
crossref_primary_10_1290_1071_2690_2001_037_0303_TNFBIP_2_0_CO_2
crossref_primary_10_1006_cyto_1998_0466
crossref_primary_10_1002_cncr_30845
crossref_primary_10_1016_S0889_8561_22_00170_9
crossref_primary_10_1046_j_1526_0968_1999_00147_x
crossref_primary_10_1002_eji_1830220224
crossref_primary_10_1016_j_febslet_2007_11_051
crossref_primary_10_1111_j_1365_2249_1992_tb06961_x
crossref_primary_10_1111_j_1365_2249_2007_03488_x
crossref_primary_10_1038_ki_1992_332
crossref_primary_10_1097_00007890_199801150_00022
ContentType Journal Article
Copyright 1991 INIST-CNRS
Copyright_xml – notice: 1991 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7T5
H94
7X8
OTOTI
5PM
DOI 10.1073/pnas.87.22.8781
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Immunology Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
OSTI.GOV
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList CrossRef


MEDLINE

AIDS and Cancer Research Abstracts

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
EISSN 1091-6490
EndPage 8784
ExternalDocumentID 5822267
10_1073_pnas_87_22_8781
2174164
19465384
87_22_8781
2355630
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-DZ
-~X
.55
.GJ
0R~
123
29P
2AX
2FS
2WC
3O-
4.4
53G
5RE
5VS
79B
85S
AACGO
AAFWJ
AANCE
ABBHK
ABOCM
ABPLY
ABPPZ
ABTLG
ABXSQ
ABZEH
ACGOD
ACIWK
ACNCT
ACPRK
ADULT
ADZLD
AENEX
AEUPB
AEXZC
AFDAS
AFFNX
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AQVQM
ASUFR
AS~
CS3
D0L
DCCCD
DIK
DNJUQ
DOOOF
DU5
DWIUU
E3Z
EBS
EJD
F20
F5P
FRP
GX1
HGD
HH5
HQ3
HTVGU
HYE
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JSODD
JST
KQ8
L7B
LU7
MVM
N9A
NEJ
N~3
O9-
OK1
P-O
PNE
PQQKQ
R.V
RHF
RHI
RNA
RNS
RPM
RXW
SA0
SJN
TN5
UKR
VOH
VQA
W8F
WH7
WHG
WOQ
WOW
X7M
XFK
XSW
Y6R
YKV
YSK
ZA5
ZCA
ZCG
~02
~KM
-
02
08R
0R
1AW
55
AAPBV
ABFLS
ABPTK
ADACO
AJYGW
AS
DZ
GJ
KM
OHM
PQEST
X
XHC
692
6TJ
AAUGY
AAYJJ
ACKIV
BKOMP
H13
IQODW
NHB
TAE
TAF
YBH
ADACV
ADQXQ
CGR
CUY
CVF
ECM
EIF
IPSME
NPM
AAYXX
CITATION
7T5
H94
7X8
OTOTI
5PM
ID FETCH-LOGICAL-c645t-4651ed2fb5b742b6d4389adf9c46a91d7bf1777edd2d4ef9cea1a11b8fdd61f03
IEDL.DBID RPM
ISSN 0027-8424
IngestDate Tue Sep 17 21:24:05 EDT 2024
Fri May 19 00:35:48 EDT 2023
Fri Aug 16 23:26:05 EDT 2024
Fri Aug 16 07:55:02 EDT 2024
Fri Aug 23 01:40:08 EDT 2024
Thu May 23 23:49:57 EDT 2024
Sun Oct 29 17:06:24 EDT 2023
Wed Nov 11 00:29:05 EST 2020
Thu May 30 08:53:04 EDT 2019
Fri Feb 02 07:06:01 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 22
Keywords Proteins
Cytotoxicity
Inhibition
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c645t-4651ed2fb5b742b6d4389adf9c46a91d7bf1777edd2d4ef9cea1a11b8fdd61f03
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://doi.org/10.1073/pnas.87.22.8781
PMID 2174164
PQID 15885654
PQPubID 23462
PageCount 4
ParticipantIDs osti_scitechconnect_5822267
pubmedcentral_primary_oai_pubmedcentral_nih_gov_55043
proquest_miscellaneous_80134332
pnas_primary_87_22_8781_fulltext
crossref_primary_10_1073_pnas_87_22_8781
pubmed_primary_2174164
proquest_miscellaneous_15885654
jstor_primary_2355630
pascalfrancis_primary_19465384
pnas_primary_87_22_8781
ProviderPackageCode RNA
PNE
PublicationCentury 1900
PublicationDate 1990-11-01
PublicationDateYYYYMMDD 1990-11-01
PublicationDate_xml – month: 11
  year: 1990
  text: 1990-11-01
  day: 01
PublicationDecade 1990
PublicationPlace Washington, DC
PublicationPlace_xml – name: Washington, DC
– name: United States
PublicationTitle Proceedings of the National Academy of Sciences - PNAS
PublicationTitleAlternate Proc Natl Acad Sci U S A
PublicationYear 1990
Publisher National Academy of Sciences of the United States of America
National Acad Sciences
Publisher_xml – name: National Academy of Sciences of the United States of America
– name: National Acad Sciences
SSID ssj0009580
Score 1.7953585
Snippet Serum ultrafiltrates (SUF) from human patients with different types of cancer contain a blocking factor (BF) that inhibits the cytolytic activity of human...
SourceID pubmedcentral
osti
proquest
crossref
pubmed
pascalfrancis
pnas
jstor
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 8781
SubjectTerms 550201 - Biochemistry- Tracer Techniques
AMINO ACID SEQUENCE
Amino acids
Analytical, structural and metabolic biochemistry
Animals
BASIC BIOLOGICAL SCIENCES
Biological and medical sciences
Cancer
Cytokines
Cytotoxicity, Immunologic - drug effects
DISEASES
ELECTROPHORESIS
Fundamental and applied biological sciences. Psychology
Gels
Humans
In Vitro Techniques
Lymphotoxin-alpha - antagonists & inhibitors
LYSIS
MEMBRANE PROTEINS
Mice
Miscellaneous
Molecular Sequence Data
MOLECULAR STRUCTURE
Molecular Weight
NECROSIS
NEOPLASMS
Neoplasms - blood
Neoplasms, Experimental - pathology
ORGANIC COMPOUNDS
PATHOLOGICAL CHANGES
PATIENTS
Peptide Fragments - blood
Phagocytes
PROTEINS
PURIFICATION
RECEPTORS
Receptors, Cell Surface - isolation & purification
Receptors, Tumor Necrosis Factor
Tumor necrosis factor receptors
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor necrosis factors
Tumors
Title Purification and Characterization of an Inhibitor (Soluble Tumor Necrosis Factor Receptor) for Tumor Necrosis Factor and Lymphotoxin Obtained from the Serum Ultrafiltrates of Human Cancer Patients
URI https://www.jstor.org/stable/2355630
http://www.pnas.org/content/87/22/8781.abstract
https://www.ncbi.nlm.nih.gov/pubmed/2174164
https://search.proquest.com/docview/15885654
https://search.proquest.com/docview/80134332
https://www.osti.gov/biblio/5822267
https://pubmed.ncbi.nlm.nih.gov/PMC55043
Volume 87
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLfYJKRdEIMNskHxgcN2SDvnw06PaGIaoKEdmLSb5U8tUutUTSLB_8cfxnv56FZEL1yqxHbjOv495-fmvd8j5KPVjnOjeaxzO4-zxJm4MMzEaaJ8IVJr0xTjnW--8-u77Ot9fj_EcdeDW2UwupyGxXIayofOt3K1NLPRT2x2e3OZo-zWbI_siTQdN-gbnd2ijzpJYPHNkmxU8xHpbBVUPS3ENEngs2AH5DnSccazrUdS75UIC3QFJoaekqqGm-X7LBeogApX-Rcb_dup8slT6uoleTHQS_qpH8YheebCK3I4GHBNzwaV6fPX5Pdtu0Y3oW5mqAqWmo12cx-aSSsP5bQMD6UGu1_TM8SpXjjatEs4DQ7HU9a0z9lDYe10Kzg4p0CEd7TBfha_AEFVU_0soQuNf004SzHMhQIZpWAS7ZK2CxidLxeddm6Nv6RLJkgNgnRNBzXY-ojcXX3-cXkdDykdYsOzvIkx87qzide5hj255haTryvr5ybjas6s0J4JIZy1ic0cFDvFFGO68NZy5i_SY7IfquDeEpo7z81cWy20Qll4LQo4UcYzdeG4tRE5G2dVrnrlDtm9cRepxEmUhZBJIhEKETnqZn3TLkk73bSInCIKJJARVNQ16HpkGpkjqeIiIpMtcDz2MkfRuiKLyJuuo7H8aYd0R430g89PRD6MGJNg8fgaRwVXtbVkeVEADc92twDWkaIuXUSOe0w-DqxHfETyLbBu6lFsfLsGbLATHe9s7uQ_v3dKDhjQnj6G8x3Zb9atew9krtET2MZ8-TbpjPgPKRBTvA
link.rule.ids 230,315,733,786,790,891,27957,27958,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BEaIXoNCCKbR74JAenHT92HWOqKIK0FQ9pFJv1j5Vi8SOYlsCfh8_jBk_0qYiB7hE8e7Ga2--GX-2Z74h5KNRlnOtuK9iM_ajwGo_0Uz7YSBdIkJjwhDznaeXfHIdfb2Jb7o87rILq8y1yob5fDHMs9smtnK50KM-Tmx0NT2LUXZr9Jg8AWsNRH-LvlbaTdq8kwDcbxREvZ6PCEfLXJbDRAyDAD4TtkueIiFnPNq4KLVxieCiCzAyjJWUJSyXa-tcoAYq7OVvfPRhWOW969T5CzLrz7ANT_k-rCs11L8eiD_-4xK8JM873ko_tZ175JHNX5G9zjOUdNDJV5-8Jr-v6hXGHzV_OZW5oXotCt3mfNLCQTvN8ttMgUNZ0QEagJpbWtUL2MwtLlNW0rYYEAWnbJfw5YQCw94yBueZ_wRoFlXxI4MpFD7zsIZi_gwFlkvB1uoFreewaC6bN6K8JR5JU6WQakT_inYys-U-uT7_PDub-F2tCF_zKK58LOluTeBUrOBmX3GDVd2lcWMdcTlmRijHhBDWmMBEFpqtZJIxlThjOHOn4QHZyYvcviU0to7rsTJKKIl680oksCG1Y_LUcmM8MujBki5bSZC0eZUvwhSxkSYiDYIUEeaR_QZM63FB2AiyeeQQwZUCy0GpXo0xTbpKY2RrXHjkaANzd7OMUQ0viTzyppmob78_Id3Sk7oumMgjxz10U3Al-H5I5raoy5TFSQL8Pto-AuhMiIJ3HjlooX53Yq0heSTesIF1P6qYb_YAshs18wbJ7_7zd8fk2WQ2vUgvvlx-OyS7DLhVmyj6nuxUq9p-AMZYqaPGQ_wBriN0Sg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BEagXoNCCKbR74JAe7HT9WNtHVIjKo1UOVMpt5X2pVhM7im0J-H38MGb8SJuKXHqJ4t21J958M_5sz35DyEctDedKcldGOnVD3yg3UUy5gZ_ZJA60DgJc73xxyc-vwm-zaNY_uqj6tMpCydwr5guvyK_b3MrlQo2HPLHx9OIsQtmt8VLb8WPyBDzWT4fb9LXabtKtPfEhBId-OGj6xLBXkVVeEnu-D58J2yVPkZQzHm5cmLrcRAjTJTga5ktmFUyZ7WpdoA4qHOV_nPR-auWda9XkBZkNZ9mlqNx4TS099eeeAOQDpuEled7zV_qpG7BHHpniFdnrI0RFR72M9clr8nfarDAPqf3raVZoqtbi0N3aT1paaKd5cZ1LCCwrOkJHkHND62YBm4XBqcor2hUFohCczRK-nFBg2lvGoJ35b4BoWZe_cjAh8dmH0RTX0VBguxR8rlnQZg4TZ_N5K85b4S9pqxVShV6wor3cbLVPriZffp6du33NCFfxMKpdLO1utG9lJOGmX3KN1d0zbVMV8ixlOpaWxXFstPZ1aKDZZCxjTCZWa87saXBAdoqyMG8JjYzlKpVaxjJD3XkZJ7CRKcuyU8O1dshoAIxYdtIgon2lHwcC8SGSWPi-QJQ5ZL8F1HqcH7TCbA45RIAJYDso2aswt0nVIkLWxmOHHG3g7tZKiqp4SeiQN62hof2uQbqlR9g-qcghxwN8BYQUfE-UFaZsKsGiJAGeH24fAbQmQOE7hxx0cL89sc6ZHBJt-MG6H9XMN3sA3a2qeYvmdw_c75g8m36eiB9fL78fkl0GFKtbL_qe7NSrxnwA4ljLozZI_APd9HbK
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Purification+and+characterization+of+an+inhibitor+%28soluble+tumor+necrosis+factor+receptor%29+for+tumor+necrosis+factor+and+lymphotoxin+obtained+from+the+serum+ultrafiltrates+of+human+cancer+patients&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=T+Gatanaga&rft.au=C+D+Hwang&rft.au=W+Kohr&rft.au=F+Cappuccini&rft.date=1990-11-01&rft.pub=National+Acad+Sciences&rft.issn=0027-8424&rft.eissn=1091-6490&rft.volume=87&rft.issue=22&rft.spage=8781&rft_id=info:doi/10.1073%2Fpnas.87.22.8781&rft_id=info%3Apmid%2F2174164&rft.externalDBID=n%2Fa&rft.externalDocID=87_22_8781
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F87%2F22.cover.gif
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F87%2F22.cover.gif